ReHeva BioSciences

Columbus, OH (April 2022) – ReHeva Biosciences, a biopharmaceutical company focused on helping people live longer and healthier with cancer through botanically derived complex drugs, is announcing thefirst patient has been enrolled and dosed in the Phase I Safety Trial for the company’s drug, RH324. ThisSafety Trial is being conducted in advanced non-small cell lung cancer (NSCLC) patients at UniversityHospitals in Cleveland.

“At ReHeva Biosciences, we do not accept that unwanted side effects and brief remission periods are an inevitable part of cancer treatment. Our transformative approach is targeting multiple tissues and mechanisms of action through novel and complex botanically derived agents to treat major diseases. We are addressing an unmet need and an opportunity to develop drugs with long term safety, efficacy, and affordability,” said Dr. Zeenia Kaul, CEO, Co-Founder and Chief Scientific Officer of ReHeva. “Having the first patients enrolled in our Phase I Safety Trial is an exciting step in making our mission a reality.”

The purpose of this clinical study is to assess the safety and tolerability of three dose levels of RH324 inpatients with advanced NSCLC who will take RH324 twice daily for 28 days. The trial will determine tolerability, as well as the feasibility of measuring plant marker compounds in the blood andurine, changes in one’s cancer through Positron Emission Tomography (PET) Imaging and the impact on quality of life. We hope to complete the study by the end of this year.

Founded in 2016 by Kaul, ReHeva Biosciences is built on more than 20 years of pre-clinical research and development. It is supported by studies published in highly regarded peer-reviewed journals showing the efficacy of a unique natural formulation with selectivity to cancer cells.

ReHeva received FDA Investigational New Drug allowance (IND) in 2018 to conduct Phase I SafetyStudy in advanced NSCLC patients. ReHeva spent the last two years further developing the formulation and proprietary assays. ReHeva’s approach relies on the multifaceted and broad spectrum benefits ofRH324, allowing it to have a positive effect on a multitude of pathways involved in cancer, as well as on specific targets within those pathways.

As a biopharmaceutical startup, ReHeva has raised more than $4 million in pre-Series A funding. More information can be found at

About RH324
RH324 is an investigational new drug manufactured by ReHeva Biosciences Inc. The botanical drug
substance retains a “full spectrum” of the plant’s natural constituents: proteins, amino acids, various fatty
acids, carbohydrates and vitamins, minerals, and phytochemicals. RH324 is being developed in
accordance with the FDA Guidance for Industry for Botanical Drug Products (Chemistry June
2004/revised Dec 2016).

About ReHeva BiosciencesFounded in 2016, ReHeva Biosciences is a clinical-stage, biopharmaceutical company focused on discovering and developing naturally occurring complex drugs. Built on a foundation of more than 20years of research on the use of naturally derived agents to treat major diseases. ReHeva is committed to finding the ideal botanical raw material and drug development processes through rigorous and advanced agriculture practices.

Newest posts

Sign up for free
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sign up right away

Sign up now and get the best insurance on the market

“Using this template has saved my marriage! I am more than thrilled!”

Gianna Johnson
Director @Company